Page 5 - Biocon Stock

GMM Pfaudler, IDBI Bank: 14 Nifty500 stocks have surged above their 200-DMA

Analysts prefer stocks trading above the 200-DMA, since they tend to perform better in a trending market. Risk management, hence, becomes comparatively easier

Biocon tanks 10% on lower-than-expected December quarter results

Due to professional differences with the chairperson on strategic priorities and the vision for the company, Dr Christiane Hamacher has stepped down as the MD of Biocon Biologics

Stocks to watch: Wipro, 3i Infotech, Biocon, SBI Life, AU Small Finance

3i Infotech Ltd has entered into definitive agreements to sell its software products business to the funds advised by Apax Partners for Rs 1,000 crore

Biocon: Street to keep an eye on CY21 launches, market share gains

Launch of a cancer drug was delayed due to Covid-19

Biocon dips 11% in three days on disappointing September quarter results

The company said profitability was impacted on account of higher R&D expenses, staff costs, other expenses and forex losses

Multiple growth levers for Biocon; ramp-up, new biosimilars to boost profit

Ramp-up and new biosimilars should help boost profit

Biocon stock: Rich valuations, regulatory news flow may add to volatility

Analysts expect Biocon to gain 20-25 per cent market share and after factoring in a 20-25 per cent price erosion in the first year, they see its earnings improving to Rs 12-16